Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXISECRET: Exercise and Semaglutide in Type 2 Diabetes
NCT04383197Unknown
- Sponsor
- University of Copenhagen
- Start
- Dec 2019
- Primary completion
- Aug 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by University of Copenhagen. Primary endpoint: Insulin secretory capacity at 12 weeks. Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04383197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04383197.